Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The purpose is to investigate the effects of 2 different treatments (drospirenone/ethinyl
estradiol versus rosiglitazone) on insulin sensitivity and androgen levels, inflammatory
markers, vascular markers and bone development in overweight adolescent females with
polycystic ovary syndrome (PCOS).
Phase:
Phase 4
Details
Lead Sponsor:
Children's Hospital of Pittsburgh Silva Arslanian
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)